Preclinical development of NaPi2b-PL2202, a novel camptothecin- based antibody-drug conjugate targeting solid tumors expressing NaPi2b

被引：0
|
作者：
Horsley, Elizabeth
Jabeen, Asma
Veillard, Nicolas
Havenith, Karin
Janghra, Narinder
Alves, Pedro
Oblette, Cecile
Kirby, Ian
Hogg, Paul W.
Zammarchi, Francesca
de Haan, Lolke
van Berkel, Patrick
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 06期
关键词：
D O I：
10.1158/1538-7445.AM2024-5085
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5085
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors
    Scribner, Juniper A.
    Hicks, Stuart W.
    Sinkevicius, Kerstin W.
    Yoder, Nicholas C.
    Diedrich, Gundo
    Brown, Jennifer G.
    Lucas, Jacquelynn
    Fuller, Megan E.
    Son, Thomas
    Dastur, Anahita
    Hooley, Jeff
    Espelin, Christopher
    Themeles, Marian
    Chen, Francine Z.
    Li, Ying
    Chiechi, Michael
    Lee, Jenny
    Barat, Bhaswati
    Widjaja, Lusiana
    Gorlatov, Sergey
    Tamura, James
    Ciccarone, Valentina
    Ab, Olga
    McEachem, Kerry A.
    Koenig, Scott
    Westin, Eric H.
    Moore, Paul A.
    Chittenden, Thomas
    Gregory, Richard J.
    Bonvini, Ezio
    Loo, Deryk
    MOLECULAR CANCER THERAPEUTICS, 2022, 21 (07) : 1047 - 1059
  • [42] Disitamab vedotin, a novel HER2-directed antibody-drug conjugate in gastric cancer and other solid tumors
    Hu, Yixuan
    Zhu, Yinxing
    Wei, Xiaowei
    Tang, Cuiju
    Zhang, Wenwen
    DRUGS OF TODAY, 2022, 58 (10) : 491 - 507
  • [43] ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in non-human primates
    Hernandez, A.
    Urosev, D.
    Wong, J.
    Lawn, S.
    Wu, K.
    Fu, L.
    Stahl, K.
    Lasalle, M.
    Alonzo, D. A.
    Yang, L.
    Sagoe-Wagner, A. P.
    Degefie, L.
    Kim, C.
    Wu, A.
    Chen, C. W.
    Higgins, R.
    Petersen, M.
    Colombo, R.
    Barnscher, S. D.
    Rich, J. R.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S5 - S5
  • [44] A novel dual drug antibody-drug conjugate targeting hTrop2 has synergetic antitumor activity in solid tumor models
    Zhu, Jie
    Zhao, Xiaobei
    Li, Eileen
    Xu, Hong
    Nie, Lei
    Chen, Gang
    Wang, Haibing
    CANCER RESEARCH, 2024, 84 (06)
  • [45] Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC).
    Kurmasheva, Raushan
    Mosse, Yael P.
    Del Pozo, Vanessa
    Earley, Eric J.
    Erickson, Stephen W.
    Groff, David
    Kolb, E. Anders
    Krytska, Kateryna
    Smith, Malcolm A.
    Tsang, Matthew
    Teicher, Beverly A.
    Gorlick, Richard Greg
    Maris, John M.
    Houghton, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [46] ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors
    Zammarchi, Francesca
    Havenith, Karin
    Chivers, Simon
    Hogg, Paul W.
    Britten, Charlie
    Dissanayake, Sandamali
    Tyrer, Peter
    Bertelli, Francois
    Hutchinson, Ian
    Masterson, Luke
    Howard, Phil
    Hartley, John A.
    van Berkel, Patrick H.
    CANCER RESEARCH, 2018, 78 (13)
  • [47] Development of a Novel IHC Assay on the BOND-III for Detection of NaPi2b in Serous Ovarian Cancer Samples to Identify Patients Eligible for Treatment with Upifitamab Rilsodotin (UpRi)
    Patel, Aatish
    Cowden, Eric
    Okeke, Nnamdi
    Skende, Olga
    Krassnoff, Paul
    Alexander, Melissa
    Mosher, Rebecca
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 1258 - 1258
  • [48] Toward clinical development of SYD985, a novel HER2-targeting antibody-drug conjugate (ADC).
    Verheijden, Gijs
    Beusker, Patrick
    Ubink, Ruud
    van der Lee, Miranda
    Groothuis, Patrick
    Goedings, Peter J.
    Egging, David
    Mattaar, Ellen
    Timmers, Macro
    Dokter, Wim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Development of a Novel IHC Assay on the BOND-III for Detection of NaPi2b in Serous Ovarian Cancer Samples to Identify Patients Eligible for Treatment with Upifitamab Rilsodotin (UpRi)
    Patel, Aatish
    Cowden, Eric
    Okeke, Nnamdi
    Skende, Olga
    Krassnoff, Paul
    Alexander, Melissa
    Mosher, Rebecca
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 1258 - 1258
  • [50] ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors
    Shin, Seol Hwa
    Ju, Eun Jin
    Park, Jin
    Ko, Eun Jung
    Kwon, Mi Ri
    Lee, Hye Won
    Son, Ga Won
    Park, Yun-Yong
    Kim, Yeon Joo
    Song, Si Yeol
    Lee, Sangkwang
    Seo, Beom Seok
    Song, Jin-A
    Lim, Sangbin
    Jung, Doohwan
    Kim, Sunyoung
    Lee, Hyangsook
    Park, Seok Soon
    Jeong, Seong-Yun
    Choi, Eun Kyung
    CANCER CELL INTERNATIONAL, 2023, 23 (01)
12345